feed,title,long_url,short_url
Benzinga,Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions,https://benzinga.com/analyst-ratings/analyst-color/23/09/34769895/discontinuation-of-opul-business-weighs-on-botox-rival-revance-therapeutics-analyst,https://da.gd/7Akr
